Articles related to Clinical Pharmacology

Multiple post-licensure studies have failed to demonstrate ticagrelor’s superiority over clopidogrel, prompting leading cardiologists to call for guideline reappraisal.

Recent research indicates that pharmaceutical nitrosamine contamination presents broader implications for drug safety, with increasing evidence of genotoxic and mutagenic effects even at trace levels.

A multicenter trial of 7,062 post-MI patients found that colchicine therapy, despite reducing C-reactive protein levels by 1.28 mg/L, did not significantly impact the composite outcome of cardiovascular death, recurrent MI, stroke, or unplanned revascularization over 3 years of follow-up.

Laboratory analysis reveals montelukast demonstrates “significant binding” to multiple brain receptors, suggesting more extensive neurological activity than previously understood.

Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”